A seven-year study of 470 patients revealed that a severe fungal lung infection once mainly seen in specific high-risk groups is increasingly affecting elderly patients and those with common cancers who are not receiving traditional high-risk treatments, suggesting current prevention strategies may be missing vulnerable populations.
Pneumocystis pneumonia (PCP) is a serious fungal lung infection that kills up to 60% of affected patients without HIV. For decades, doctors knew which patients were at the highest risk: those receiving immune-suppressing drugs or those with blood cancers.
However, a comprehensive seven-year study from Taiwan revealed that such a dangerous infection is increasingly striking patients who fall outside these traditional categories. The study is published in Journal of Infection.
Dr. Ting-Wei Kao and his colleagues at National Taiwan University analyzed 470 non-HIV individuals diagnosed with PCP across seven major hospitals between 2016 and 2023. What they discovered challenges current medical understanding and prevention strategies.
PCP risk shifts to new groups
The most striking finding was a dramatic shift in who develops this infection. By 2023, nearly 70% of PCP cases occurred in patients not receiving the medications traditionally associated with the highest risk.
"We're seeing a fundamental change in the risk profile," the researchers note. Elderly patients were particularly affected—more than one-third of those aged 85 and older who developed PCP were taking only medications not conventionally linked to this infection.
The study also revealed that solid cancers have now surpassed blood cancers as the most common underlying condition in PCP patients. Additionally, nearly one-third of patients had no previously recognized risk diseases at all. These patients were older and had more common health conditions like high blood pressure, diabetes, and heart disease.
Outcomes and overlooked vulnerabilities
The research team found concerning patterns in disease outcomes. Patients with solid cancers faced the worst prognosis, with hospital death rates exceeding 60%. Overall, half of all patients died during hospitalization, and the disease was severe across all groups, with more than 60% required intensive care and three-quarters experienced respiratory failure.
Current prevention guidelines focus primarily on patients receiving specific high-risk medications. However, this study suggested many vulnerable patients were being overlooked. The researchers found significant variation in medication patterns across different diseases, indicating that prevention strategies need to be more nuanced and disease-specific rather than one-size-fits-all.
The increasing proportion of cases in elderly patients with multiple common health conditions suggests that aging itself combined with everyday medical problems might create vulnerability through mechanisms not yet fully understood. Advanced age brings natural immune system decline that may compound subtle immune weaknesses not captured by current risk assessment approaches.
Implications for prevention and clinical practice
These findings have immediate implications for clinical practice. Doctors may need to maintain higher suspicion for PCP in broader patient populations, particularly elderly patients with solid cancers and multiple health conditions, even when they are not receiving traditionally high-risk treatments.
The research team emphasizes that more sophisticated risk assessment tools are needed, such as ones that consider age, overall health burden, and disease-specific factors beyond just medication exposure.
"These evolving patterns suggest that current prophylaxis guidelines, which focus primarily on patients receiving established high-risk medications, may need reconsideration. We're missing a significant proportion of vulnerable patients, particularly those with solid cancers and elderly individuals with multiple comorbidities," says Prof. Jung-Yien Chien, corresponding author of the study.
"More targeted prophylaxis strategies that balance preventing this deadly infection against unnecessary antimicrobial exposure are urgently needed."
To see article on Medical Xpress: https://medicalxpress.com/news/2025-11-pneumocystis-pneumonia-unexpected-patient-groups.html